Author Archives: admin


Stem Cell Clinic > Articles by: admin

Rare stem cells hold potential for infertility treatments …

By Stem Cell Medical Center

Rare stem cells in testis that produce a biomarker protein called PAX7 help give rise to new sperm cells -- and may hold a key to restoring fertility, research by scientists at UT Southwestern Medical Center suggests.

Researchers studying infertility in mouse models found that, unlike similar types of cells that develop into sperm, the stem cells that express PAX7 can survive treatment with toxic drugs and radiation. If the findings hold true in people, they eventually could lead to new strategies to restore or protect fertility in men undergoing cancer treatment.

"Unfortunately, many cancer treatments negatively impact fertility, and men who receive such treatments are at high risk of losing their fertility. This is of great concern among cancer patients," said Dr. Diego H. Castrillon, Associate Professor of Pathology and Director of Investigative Pathology. "The PAX7 stem cells we identified proved highly resistant to cancer treatments, suggesting that they may be the cells responsible for the recovery of fertility following such treatments."

Infertility, which the Centers for Disease Control estimates affects as many as 4.7 million men in the United States, is a key complication of cancer treatments, such as chemotherapy and radiation therapy.

The new findings, presented in the Journal of Clinical Investigation, provide valuable insight into the process of sperm development. Known as spermatogenesis, sperm development is driven by a population of "immature" stem cells called progenitors in the testes. These cells gradually "mature" into fully differentiated sperm cells. Dr. Castrillon and his team tracked progenitor cells that express the protein PAX7 in mouse testes, and found that these cells gradually give rise to mature sperm.

"We have long known that male fertility is driven by rare stem cells within the testes, but the precise identity of these stem cells has been disputed," said Dr. Castrillon, who holds the John H. Childers, M.D. Professorship in Pathology. "Our findings suggest that these rare PAX7 cells are the key cells within the testes that are ultimately responsible for male fertility."

Importantly, even after exposure to toxic chemotherapy or radiation treatments, the PAX7-expressing cells continued to divide and thus could contribute to restoring sperm development.

Story Source:

The above story is based on materials provided by UT Southwestern Medical Center. Note: Materials may be edited for content and length.

See the original post:
Rare stem cells hold potential for infertility treatments ...

Stem Cell Therapy for Chronic Illness and So Called untreatable Diseases – Video

By Uncategorized


Stem Cell Therapy for Chronic Illness and So Called untreatable Diseases
Stem Cell Therapy with Mesenchymal stem cells are pluripotent and adult cells with fibroblastoid morphology and plasticity, toward various cell lineages such as chondrocytes, osteocytes and...

By: enjades

See the article here:
Stem Cell Therapy for Chronic Illness and So Called untreatable Diseases - Video

How to tell good stem cells from the bad

By Stem Cell Medicine

Sep 05, 2014 by Bill Hathaway Separating the good stem cells from the bad. Credit: Matthew Chock, NYC

The promise of embryonic stem cell research has been thwarted by an inability to answer a simple question: How do you know a good stem cell from a bad one?

Yale researchers report in the Sept. 4 issue of the journal Cell Stem Cell that they have found a marker that predicts which batch of personalized stem cells will develop into a variety of tissue types and which will develop into unusable placental or tumor-like tissues.

Scientists have been unable to capitalize on revolutionary findings in 2006 that adult cells could be made young again with the simple introduction of four factors. Hopes were raised that doctors would soon have access to unlimited supplies of a patient's own iPSCsinduced pluripotent stem cellsthat could be used to repair many types of tissue damage. However, efforts to direct these cells to therapeutic goals have proved difficult. Many attempts to use cells clinically have failed because they form tumors instead of the desired tissue.

The team of Yale Stem Cell Center researchers led by senior author Andrew Xiao identified a variant histonea protein that helps package DNAwhich can predict the developmental path of iPSC cells in mice. An accompanying paper in the same journal by researchers at the Whitehead Institute at MIT and Hebrew University in Israel also identifies at different marker that also appears to predict stem cell fate.

"The trend is to raise the standards and quality very high, so we can think about using these cells in clinic," Xiao said. "With our assay, we have a reliable molecular marker that can tell what is a good cell and what is a bad one."

Explore further: New reprogramming factor cocktail produces therapy-grade induced pluripotent stem cells

Journal reference: Cell Stem Cell

Provided by Yale University

Induced pluripotent stem cells (iPSCs)adult cells reprogrammed back to an embryonic stem cell-like statemay hold the potential to cure damaged nerves, regrow limbs and organs, and perfectly model a ...

View post:
How to tell good stem cells from the bad

Disease in a dish approach could aid Huntington's disease discovery

By Stem Cell Medicine

PUBLIC RELEASE DATE:

5-Sep-2014

Contact: Lisa Newbern lisa.newbern@emory.edu 404-727-7709 Emory Health Sciences

Creating induced pluripotent stem cells or iPS cells allows researchers to establish "disease in a dish" models of conditions ranging from Alzheimer's disease to diabetes. Scientists at Yerkes National Primate Research Center have now applied the technology to a model of Huntington's disease (HD) in transgenic nonhuman primates, allowing them to conveniently assess the efficacy of potential therapies on neuronal cells in the laboratory.

The results were published in Stem Cell Reports.

"A highlight of our model is that our progenitor cells and neurons developed cellular features of HD such as intranuclear inclusions of mutant Huntingtin protein, which most of the currently available cell models do not present," says senior author Anthony Chan, PhD, DVM, associate professor of human genetics at Emory University School of Medicine and Yerkes National Primate Research Center. "We could use these features as a readout for therapy using drugs or a genetic manipulation."

Chan and his colleagues were the first in the world to establish a transgenic nonhuman primate model of HD. HD is an inherited neurodegenerative disorder that leads to the appearance of uncontrolled movements and cognitive impairments, usually in adulthood. It is caused by a mutation that introduces an expanded region where one amino acid (glutamine) is repeated dozens of times in the huntingtin protein.

The non-human primate model has extra copies of the huntingtin gene that contains the expanded glutamine repeats. In the non-human primate model, motor and cognitive deficits appear more quickly than in most cases of Huntington's disease in humans, becoming noticeable within the first two years of the monkeys' development.

First author Richard Carter, PhD, a graduate of Emory's Genetics and Molecular Biology doctoral program, and his colleagues created iPS cells from the transgenic monkeys by reprogramming cells derived from the skin or dental pulp. This technique uses retroviruses to introduce reprogramming factors into somatic cells and induces a fraction of them to become pluripotent stem cells. Pluripotent stem cells are able to differentiate into any type of cell in the body, under the right conditions.

Carter and colleagues induced the iPS cells to become neural progenitor cells and then differentiated neurons. The iPS-derived neural cells developed intracellular and intranuclear aggregates of the mutant huntingtin protein, a classic sign of Huntington's pathology, as well as an increased sensitivity to oxidative stress.

Excerpt from:
Disease in a dish approach could aid Huntington's disease discovery

DAP-funded stem cell research a wrong priority

By Stem Cell Treatment

From the perspective of a community physician, the stem cell research, at this point, is not a priority. Given the daunting task of not only curing the present crop of diseases but also preventing them, and of course, building the human resource as the backbone of the health care system these should be the priority. Joseph Carabeo, convenor, Rx Abolish Pork Barrel Movement

By ANNE MARXZE D. UMIL Bulatlat.com

MANILA Eleazar Sobinsky, president of the Lung Center of the Philippines Employees Association-Alliance of Health Workers cannot decipher how the Disbursement Acceleration Program (DAP) has helped the poor. Of the P115 million ($263,822) DAP funds received by LCP, P70 million ($160,587) was spent for the stem cell research project and the rest was spent for the procurement of equipment.

He said if the DAP has helped the poor, why are there more indigent patients waiting in line at the LCPs out-patient department?

Joseph Carabeo, convenor of the Rx Abolish Pork Barrel Movement and a community doctor for the past 28 years, said that the stem cell research project does not even help solve the longtime health problems of Filipinos.

The stem cell research in LCP is a mispriority, said Carabeo in an interview with Bulatlat.com. There are many problems in the health sector that has to be addressed. We think, the DOH is merely riding the bandwagon on the stem cell research intervention in health care, wellness and primarily rejuvenation, Carabeo said.

Eleazar Sobinsky, union president of the Lung Center Employees Union said if the DAP has helped the poor, why are there more indigent patients waiting in line at the LCPs out-patient department? (Photo by A. Umil/ Bulatlat.com)

Stem cells according to http://www.stemcellnetwork.ca are the precursors of all cells in the human body.

Stem cells are very special, powerful cells found in both humans and non-human animals. They have been called the centerpiece of regenerative medicine medicine that involves growing new cells, tissues and organs to replace or repair those damaged by injury, disease or aging, the website said.

In the Philippines, Carabeo said, the medical community is not even united in the use of stem cell therapy in curing diseases. He said it is still under research in the Philippines. The Philippine Society of Endocrinology and Metabolism (PSEM) for one has even warned the public on the use of stem cell therapy as treatment for diabetes.

More here:
DAP-funded stem cell research a wrong priority

Stem Cells Star in Marriage of Art and Science

By Stem Cell Medical Center

By Daniella Walsh on September 04th, 2014

By Daniella Walsh | LB Indy

Leslies stem cell

Janet Dreyer earned a doctorate in molecular biology, but in her 50s enrolled at the Pasadena College of Art and Design and became hooked on art. After a hiatus from both science and art for travel, shes back to art, creating a work that combines her training in both fields, The Stem Cell Scientist.

Dreyers computer generated work came to life at the request of Laguna Beach glass and multi-media artist Leslie Davis, who organized The Art of Stem Cells. The show features conceptual works by 29 artists. Their themes address debilitating diseases and injuries and the work of scientists trying to find cures. The month-long exhibition opens Saturday, Sept. 6, at the Orange County Center for Contemporary Art in Santa Ana.

Dreyer delved into history when she built a mosaic for the show. The work includes references to the regenerating powers of the Egyptian scarab god Khepri, showing him rolling a cell instead of the sun, among other images. I chose the mosaic format because the tiles create a sense of motion reminding me of developing cells, Dreyer said.

The exhibitions opening and closing receptions will not only showcase what results when artists interact with 23 scientists, but also introduce art patrons to researchers and examples of their state-of-the art stem cell pursuits. Half of all proceeds will benefit research at the center, led for the past eight years by Dr. Peter Donovan, to whom the show is dedicated.

With a keen interest in science and particularly stem cell therapy, Davis has forged a connection to UC Irvines Sue & Bill Gross Stem Cell Research Center. But since 2005, Davis twin interests have yielded three other medical related art exhibitions, including one for Mission Hospital.

It was her brainpower that led to pairing center researchers with artists selected on the strength and nature of their work.

Here is the original post:
Stem Cells Star in Marriage of Art and Science

UT Southwestern Scientists Identify Rare Stem Cells in Testis That Hold Potential for Infertility Treatments

By Stem Cell Medical Center

Contact Information

Available for logged-in reporters only

Newswise DALLAS Sept. 4, 2014 Rare stem cells in testis that produce a biomarker protein called PAX7 help give rise to new sperm cells and may hold a key to restoring fertility, research by scientists at UT Southwestern Medical Center suggests.

Researchers studying infertility in mouse models found that, unlike similar types of cells that develop into sperm, the stem cells that express PAX7 can survive treatment with toxic drugs and radiation. If the findings hold true in people, they eventually could lead to new strategies to restore or protect fertility in men undergoing cancer treatment.

Unfortunately, many cancer treatments negatively impact fertility, and men who receive such treatments are at high risk of losing their fertility. This is of great concern among cancer patients, said Dr. Diego H. Castrillon, Associate Professor of Pathology and Director of Investigative Pathology. The PAX7 stem cells we identified proved highly resistant to cancer treatments, suggesting that they may be the cells responsible for the recovery of fertility following such treatments.

Infertility, which the Centers for Disease Control estimates affects as many as 4.7 million men in the United States, is a key complication of cancer treatments, such as chemotherapy and radiation therapy.

The new findings, presented in the Journal of Clinical Investigation, provide valuable insight into the process of sperm development. Known as spermatogenesis, sperm development is driven by a population of immature stem cells called progenitors in the testes. These cells gradually mature into fully differentiated sperm cells. Dr. Castrillon and his team tracked progenitor cells that express the protein PAX7 in mouse testes, and found that these cells gradually give rise to mature sperm.

We have long known that male fertility is driven by rare stem cells within the testes, but the precise identity of these stem cells has been disputed, said Dr. Castrillon, who holds the John H. Childers, M.D. Professorship in Pathology. Our findings suggest that these rare PAX7 cells are the key cells within the testes that are ultimately responsible for male fertility.

Importantly, even after exposure to toxic chemotherapy or radiation treatments, the PAX7-expressing cells continued to divide and thus could contribute to restoring sperm development.

First author Gina Aloisio, a student in UT Southwesterns Medical Scientist Training Program, is the recipient of a Fellowship Award from the UT Southwestern Cecil H. and Ida Green Center for Reproductive Biology Sciences. Other UT Southwestern researchers involved in the work include Dr. Kent Hamra, Assistant Professor of Pharmacology; Dr. James Amatruda, Associate Professor of Pediatrics, Internal Medicine, and Molecular Biology, the Horchow Family Scholar in Pediatrics and holder of the Nearburg Family Professorship in Pediatric Oncology Research; Dr. Anita Sengupta, Assistant Professor of Pathology; Dr. Ileana Cuevas, Instructor of Pathology; Dr. Yuji Nakada, Instructor of Pathology; Abhijit Bugde, Department of Cell Biology; graduate student researchers Hatice Saatcioglu, Christopher Pea, and Hema Manjunath; and former UT Southwestern researchers Dr. Michael Baker, Dr. Edward Tarnawa, and Jishnu Mukherjee.

Read more:
UT Southwestern Scientists Identify Rare Stem Cells in Testis That Hold Potential for Infertility Treatments

Caribbean International Holdings (CIHN) Announces Change in Control; Seasoned Veteran in Stem Cell Industry Appointed …

By Stem Cell Medical Center

SOURCE: Caribbean International Holdings, Inc.

Mark Farber MD, PhD, MS Received Degrees From Brown University and SUNY; During His Time at Harvard Medical School He Developed Bioreactor Designs for Stem Cell Based Tissue Engineered Heart Valves

SARASOTA, FL--(Marketwired - September 04, 2014) - Caribbean International Holdings (PINKSHEETS: CIHN) through its subsidiary, Regenerative BioScience, Inc. ("RBS"), announced today that on August 27, 2014, a private investment group, J3 Financial, has acquired a controlling interest in the Company. Former CEO and former controlling shareholder, Steven Swank has resigned as of that same date; and effective as of August 28, 2014, the Company has appointed Mark Farber MD, PhD, MS as the new CEO of CIHN.

A spokesperson for J3 stated that: "We had been tracking CIHN for some time and found its business model very attractive. We feel that this is a company that is ready to emerge and being able to acquire the talents and services of someone like Dr. Farber, will help us establish a sound foundation for future growth. We feel very lucky to have him onboard."

The Company also said that it intends to identify, recruit and hire additional industry professionals within the emerging stem cell industry as it builds the infrastructure to support a solid but steady growth. It will also be adding administrative and other veteran executives in key positions.

The Company spokesperson also said that the Company feels it is important in today's market to keep its shareholders fully abreast of ongoing events and or news and it plans on keeping the market up to date in order to remain fully transparent with the Company's current and/or potential future shareholders and the market at large. In that light, management of the Company will shortly be releasing a Shareholder Update and other pertinent information as it becomes available.

Below is a brief background and bio on the new CEO of CIHN, Mark Farber, MD, PhD, MS.

Dr. Mark Farber received his undergraduate degree in Chemical Engineering from Brown University in Providence, RI in 2001, followed by a Masters in Science in Engineering from Brown University in 2003.He received his MD/PhD combined degree from SUNY Downstate Medical Center in Brooklyn, NY in 2013.His PhD project titled "Simultaneous functional diffuse optical tomography and EEG in freely moving rats" involved developing an emerging non-invasive optical imaging technology to investigate brain blood flow in anesthetized, freely foraging, and sleeping rats.

During the development of the diffuse optical tomography optical imager, Dr. Farber's research generated over $7 million in grants, including $130,000 from the competitive NIH Ruth Kirschstein National Research Service Award for MD/PhD students from the NIH/NINDS.The technology behind his PhD project for rat brain imaging was sold for over $750,000, and with the assistance of Dr. Farber his technology has been adapted for use in macaque research, clinical research, and the development of brain-machine interfaces.

Prior to completing his education in medicine and engineering, Dr. Farber spent three years working in developing stem cell bioreactors for use in research and tissue engineering.After completing his MS in Engineering, Dr. Farber briefly worked at ViaCell Inc. where he developed bioreactors to maximize stem cell yields from umbilical cord blood cultures.He then moved on to Harvard Medical School, where he worked in the Cardiovascular Pathology department and participated in research projects involving atherosclerosis, heart valve disease, embryology, and tissue engineering.During this time he initiated investigations into novel computerized methods of tissue collagen detection and quantification and developed bioreactor designs for stem cell based tissue engineered heart valves.

Read the rest here:
Caribbean International Holdings (CIHN) Announces Change in Control; Seasoned Veteran in Stem Cell Industry Appointed ...

How to tell good stem cells from the bad: Yale researchers answer key question

By Stem Cell Clinic

The promise of embryonic stem cell research has been thwarted by an inability to answer a simple question: How do you know a good stem cell from a bad one?

Yale researchers report in the Sept. 4 issue of the journal Cell Stem Cell that they have found a marker that predicts which batch of personalized stem cells will develop into a variety of tissue types and which will develop into unusable placental or tumor-like tissues.

Scientists have been unable to capitalize on revolutionary findings in 2006 that adult cells could be made young again with the simple introduction of four factors. Hopes were raised that doctors would soon have access to unlimited supplies of a patients own iPSCs induced pluripotent stem cells that could be used to repair many types of tissue damage. However, efforts to direct these cells to therapeutic goals have proved difficult. Many attempts to use cells clinically have failed because they form tumors instead of the desired tissue.

The team of Yale Stem Cell Center researchers led by senior author Andrew Xiao identified a variant histone a protein that helps package DNA which can predict the developmental path of iPSC cells in mice. An accompanying paper in the same journal by researchers at the Whitehead Institute at MIT and Hebrew University in Israel also identifies at different marker that also appears to predict stem cell fate.

The trend is to raise the standards and quality very high, so we can think about using these cells in clinic, Xiao said. With our assay, we have a reliable molecular marker that can tell what is a good cell and what is a bad one.

Lead author of the paper is Tao Wu of Yale.

Research is funded by Yale and Connecticut Stem Cell Foundation.

More here:
How to tell good stem cells from the bad: Yale researchers answer key question

New protagonist in cell reprogramming discovered

By Uncategorized

PUBLIC RELEASE DATE:

4-Sep-2014

Contact: Laia Cendrs laia.cendros@crg.eu 34-933-160-237 Center for Genomic Regulation

This news release is available in Spanish.

The protein Nanog, a transcription factor, is key to maintaining stem cells in a pluripotent state. Researchers from the Centre for Genomic Regulation have been investigating the role of this protein, and have just published an article in the prestigious journal Cell Reports where they reveal the mechanism whereby Nanog acts. The scientists have discovered that Nanog involves other agents and they have been able to detail their dynamics. In particular, by studying another protein that is also involved in cell reprogramming (beta-catenin) they have been able to improve the knowledge of Nanog's functioning.

Cell renewal is a natural process that takes place constantly in our body. For this to happen, we have stem cells that are responsible for generating new cells to replenish and renew those that die. Stem cells give rise to undifferentiated pluripotent cells which have the ability to become any cell type. These pluripotent cells follow a differentiation path towards specialisation, which can produce any cell type from neurones to skin.

The scientists want to understand the mechanisms that allow stem cells to either differentiate or remain pluripotent. There are also many studies that seek to reverse this process, to enable already differentiated cells to be reprogrammed and become pluripotent. Knowing all the players in these processes is of vital importance for understanding how stem cells work and allowing progress in regenerative medicine.

"We knew that Nanog was somehow involved in keeping stem cells pluripotent; now we know which mechanism it uses and we understand better how it works", explains Luca Marucci, one of the authors of the work from the cell reprogramming and regeneration laboratory at the CRG, led by researcher Pia Cosma. "Studying this process has allowed us to discover not only Nanog's key role in reprogramming, but also the dynamics of another protein, known as beta-catenin. We now know that beta-catenin, just like Nanog, continuously fluctuates in the cell and does not only appear when reprogramming is activated", adds Elisa Pedone, co-author of the work from the same laboratory.

In order to understand and define parameters for the activity of both proteins, the researchers have developed a mathematical model that could explain this dynamic. The model could be useful for understanding the behaviour of these proteins in the cell both over time and in different situations.

We are talking about a basic discovery on the functioning and dynamics of stem cell reprogramming. An ever-more studied process that holds great hope for the medicine of the future. The laboratory at the Centre for Genomic Regulation led by the ICREA research professor, Pia Cosma, is making a definitive contribution to this knowledge. Her group looks at basic mechanisms that orchestrate cell differentiation and reprogramming, right up to concrete reprogramming methods for repairing damage in certain tissues.

Visit link:
New protagonist in cell reprogramming discovered

→←